Renteria-Flores Francisco Israel, García-Chagollán Mariel, Jave-Suárez Luis Felipe
Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Jalisco, Mexico.
Division of Immunology, Biomedical Research Centre of the West, Mexican Social Security Institute, Guadalajara 44340, Jalisco, Mexico.
Vaccines (Basel). 2024 Aug 27;12(9):968. doi: 10.3390/vaccines12090968.
From the first report in 1891 by Dr. Coley of the effective treatment of tumors in 1000 patients with Streptococcus and the first successful use of bacterial vectors for transferring therapeutic genes in 1980 by Dr. Schnaffer, bactofection has been shown to be a promising strategy in the fields of vaccination, gene therapy, and cancer therapy. This review describes the general theory of bactofection and its advantages, disadvantages, challenges, and expectations, compiling the most notable advances in 14 vaccination studies, 27 cancer therapy studies, and 13 clinical trials. It also describes the current scope of bactofection and promising results. The extensive knowledge of biology, as well as the multiple adequacies of the Ty21a vaccination platform, has allowed notable developments worldwide that have mainly been reflected in therapeutic efforts against cancer. In this regard, we strongly recommend the creation of a recombinant Ty21a model that constitutively expresses the GtgE protease from , allowing this vector to be used in animal trials, thus enhancing the likelihood of favorable results that could quickly transition to clinical trials. From the current perspective, it is necessary to explore a greater diversity of bacterial vectors and find the best combination of implemented attenuations, generating personalized models that guarantee the maximum effectiveness in cancer therapy and vaccination.
从1891年科利医生首次报告用链球菌有效治疗1000例肿瘤患者，到1980年施纳弗医生首次成功使用细菌载体转移治疗性基因以来，细菌转染已被证明在疫苗接种、基因治疗和癌症治疗领域是一种有前景的策略。这篇综述描述了细菌转染的一般理论及其优缺点、挑战和期望，汇编了14项疫苗接种研究、27项癌症治疗研究和13项临床试验中最显著的进展。它还描述了细菌转染的当前范围和有前景的结果。对生物学的广泛了解，以及Ty21a疫苗接种平台的多种适用性，在全球范围内带来了显著进展，主要体现在抗癌治疗方面。在这方面，我们强烈建议创建一种重组Ty21a模型，该模型组成性表达来自[具体来源未提及]的GtgE蛋白酶，使这种载体能够用于动物试验，从而提高迅速过渡到临床试验的良好结果的可能性。从当前角度来看，有必要探索更多种类的细菌载体，并找到实施减毒的最佳组合，生成个性化模型，以确保在癌症治疗和疫苗接种中达到最大效果。
